All Roads Lead to Change: Advance the Representation of African Americans with MS in Clinical Trials

Release Date: February 1, 2023
Expiration Date: August 31, 2024
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern browsers and mobile devices

Expert Faculty:


	Heidi Crayton, MD Clinical Neurologist MS Center of Greater Washington Click here for biography

	Jacqueline Faulkner Rosenthal, MD Clinical Neurologist Andrew C. Carlos Multiple Sclerosis Institute Shepherd Center, Atlanta Click here for biography

	Victoria Reese Co-Founder and CEO We Are ILL Click here for biography

Target Audience
This activity is designed to meet the educational needs of a broad audience of health care providers including neurologists, primary care providers, registered nurses, ER providers, social workers, and case managers involved in treatment and management of Black patients with MS.

Statement of Need/Program Overview
The African American population is underrepresented in clinical trials today. This program will look at evidence-based strategies for health care providers to shift this current paradigm and will address some obstacles that impact minority participation in MS clinical trials.

Educational Objectives
After completing this activity, the participant should be better able to:

Apply strategies to address the underrepresentation of African Americans in MS clinical trials
Implement evidence-based strategies that will have a meaningful impact on the African American MS community

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Multiple Sclerosis Association of America, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-320-H01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

*Name of Faculty*	*Reported Financial Relationship*
Heidi Crayton, MD	Consultant/Advisory Board: Biogen; Sanofi; EMD Serono; Janssen; Bristol Myers Squibb; Novartis Fees for Non-CE Services: Biogen; Sanofi; EMD Serono; Janssen; Bristol Myers Squibb Contracted Research: Biogen, Sanofi, EMD Serono, Atara, Anokion, Novartis
Jacqueline Faulkner Rosenthal, MD	Consultant/Advisory Board: Horizon, TG, EMD Serono, Alexion, Genentech
Victoria Reese	No financial interest/relationships relating to the topic of this activity

The PIM planners and managers have nothing to disclose.
The MSAA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.